Can primary hyperparathyroidism cause elevated LDL cholesterol in a patient with chronic pancreatitis‑related malabsorption who has no coronary or carotid atherosclerotic plaque?

Primary Hyperparathyroidism Does Not Explain This Clinical Picture

Primary hyperparathyroidism (PHPT) is unlikely to account for elevated LDL cholesterol in this patient, and the absence of atherosclerotic plaque despite hyperlipidemia is better explained by the protective effect of malabsorption preventing cholesterol deposition rather than any unique property of PHPT.

The Evidence on PHPT and Lipid Metabolism

The relationship between PHPT and lipid abnormalities is inconsistent and generally weak:

• Most studies show no significant lipid changes with PHPT. A controlled study of 24 patients found that mean values for total cholesterol, triglycerides, LDL-C, and VLDL-C did not change significantly after surgical cure of hyperparathyroidism 1. The only consistent finding was lower HDL cholesterol in PHPT patients both before and after surgery 1.

• When lipid abnormalities do occur with PHPT, they are modest. In normocalcemic PHPT patients identified through population screening, there were elevated LDL/HDL ratios and VLDL-cholesterol, but these improved after parathyroidectomy 2. However, this represents a specific subset of PHPT patients, not the typical presentation.

• The evidence is contradictory. Historical data shows conflicting results, with some authors finding increased serum lipids with PTH elevation while others found decreased cholesterol and triglycerides 3. This inconsistency suggests PHPT is not a primary driver of dyslipidemia.

Why PHPT Cannot Explain This Patient's Presentation

The clinical scenario described has several features that argue against PHPT as the cause:

1. PHPT typically increases cardiovascular risk and plaque formation, not the opposite:

• PHPT is associated with increased coronary artery calcium scores and greater calcific plaque burden 4
• Patients with PHPT show increased carotid intima-media thickness and endothelial dysfunction 5
• The absence of plaque in this patient contradicts what we see in PHPT

2. The malabsorption from chronic pancreatitis is the key factor:

• Chronic pancreatitis causes fat malabsorption, which paradoxically can lead to elevated serum lipids due to impaired clearance mechanisms
• The absence of plaque despite high LDL suggests the lipids are not being deposited in vessel walls—likely because malabsorption creates a metabolic state where lipoproteins are altered in ways that reduce atherogenicity
• Interestingly, PHPT itself can cause chronic pancreatitis through hypercalcemia 6, but this would not explain the lipid pattern

3. The lipid abnormalities in PHPT don't match this pattern:

• When PHPT affects lipids, it typically causes modest increases in LDL/HDL ratio and triglycerides 2
• The dramatic elevation of LDL without plaque formation is more consistent with malabsorption-related dyslipidemia

Clinical Algorithm for This Patient

Step 1: Confirm the PHPT diagnosis is accurate (elevated calcium with inappropriately normal or elevated PTH, excluding secondary causes)

Step 2: Evaluate whether the chronic pancreatitis is caused by the PHPT (hypercalcemia-induced pancreatitis) 6

• If yes, treating PHPT may improve both conditions
• If no, these are separate issues

Step 3: Address the elevated LDL based on the Endocrine Society guidelines 7:

• Rule out hypothyroidism as a cause of hyperlipidemia before starting lipid-lowering medications
• The elevated LDL is most likely due to malabsorption from chronic pancreatitis, not PHPT

Step 4: The absence of plaque is actually reassuring and suggests:

• The duration of hyperlipidemia may be relatively short
• The malabsorption state may be creating a paradoxically protective metabolic environment
• Standard cardiovascular risk stratification may not apply in this unique metabolic context

Critical Pitfall to Avoid

Do not attribute the elevated LDL to PHPT and delay appropriate lipid management. The evidence clearly shows PHPT has minimal and inconsistent effects on LDL cholesterol 1. Focus instead on optimizing pancreatic enzyme replacement to improve fat absorption, which may normalize the lipid profile. If PHPT requires treatment based on standard criteria (symptomatic disease, end-organ damage), treat it for those indications—not for lipid management.